Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published data with mRNA vaccines, predicting a promising efficacy of ReCOV in preventing SARS-COV-2 induced diseases ReCOV...
Planet Innovation acquires BIT Group’s North American operations, doubling its medtech manufacturing capacity
MELBOURNE, Australia, Nov. 12, 2021 /PRNewswire/ -- Planet Innovation (PI) has acquired the North American operations of global regulated medical device manufacturer, BIT Analytical Instruments GmbH. The acquisition solidifies PI's commitment to grow its US manufacturing capabilities to support its growing US customer base. Based in Irvine, California, the addition of...
Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections
SINGAPORE, Nov. 12, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes across the United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose symptoms can include colds and the flu. Tabernacle Health Group Launches Revolutionary Immunity Booster! Natural Health...
Patients benefited from telemedicine during COVID-19, says new white paper from Healint
Longitudinal surveys conducted via HeRO™, Healint's proprietary real-world patient insights platform, reveal that 84% would choose telemedicine if it was available, with a preference for follow-up consultations A 9-month follow-up questionnaire was sent to evaluate changes in patients' expectations and experience with teleconsultation The main advantages of the teleconsultation...
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
- Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be demonstrated during the event in booth #423 - One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient response to immunotherapy across multiple cancer types SEOUL, South Korea, Nov. 11,...
Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics
SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small molecule oncology research programs. Turning Point is a precision oncology company...
Happiness Biotech Group Limited Announces Name Change to Happiness Development Group Limited and Re-Designation of Its Ordinary Shares
NANPING, China, Nov. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited ("Happiness" or the "Company"), (NASDAQ: HAPP), is pleased to announce that effective on November 12, 2021, the Company will change its name to "Happiness Development Group Limited" (the "Name Change"). In addition, the Company re-designated its authorized ordinary shares, par value $0.0005 each, into Class A ordinary shares, par...
PNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled...
IDKLIC Awarded VPHARMA Contract Extension for Five Additional Years
BRUSSELS, Nov. 11, 2021 /PRNewswire/ -- iDklic announced the extension of technology partnership with VPHARMA for an additional five years, providing the PharmaSeen window shopping digital signage solution to 40 VPHARMA pharmacy locations throughout Belgium. iDklic, part of the STRATACACHE family of marketing technology companies, delivers customer experiences inside pharmacies and healthcare companies...
Gmax’s GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose, placeable controlled, double blind, randomized, dose escalating study, with 6 dose...
